Cover Image
Read Now

Switching botulinum toxin A products for patients with upper limb spasticity or cervical dystonia a review of clinical effectiveness

The four Botulinum neurotoxin type A (BoNT-A) products have different complex protein structures and differ in their molecular weights, pharmacologic profiles, and potency. Because each BoNT-A product has a different potency, they are not considered interchangeable by Health Canada and dosages may n...

Full description

Bibliographic Details
Main Authors: Pohar, Ron, Rabb, Danielle (Author)
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) CADTH 2018, February 9, 2018
Series:CADTH rapid response report: summary with critical appraisal
Subjects:
Muscle Spasticity / Drug Therapy
Drug Substitution
Dystonia / Drug Therapy
Treatment Outcome
Botulinum Toxins, Type A / Therapeutic Use
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 02197nam a2200301 u 4500
001 EB001865363
003 EBX01000000000000001029443
005 00000000000000.0
007 tu|||||||||||||||||||||
008 190504 r ||| eng
100 1 |a Pohar, Ron 
245 0 0 |a Switching botulinum toxin A products for patients with upper limb spasticity or cervical dystonia  |h Elektronische Ressource  |b a review of clinical effectiveness  |c Ron Pohar, Danielle Rabb 
260 |a Ottawa (ON)  |b CADTH  |c 2018, February 9, 2018 
300 |a 1 PDF file (24 pages)  |b illustration 
505 0 |a Includes bibliographical references 
653 |a Muscle Spasticity / drug therapy 
653 |a Drug Substitution 
653 |a Dystonia / drug therapy 
653 |a Treatment Outcome 
653 |a Botulinum Toxins, Type A / therapeutic use 
700 1 |a Rabb, Danielle  |e [author] 
710 2 |a Canadian Agency for Drugs and Technologies in Health 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a CADTH rapid response report: summary with critical appraisal 
856 4 0 |u https://www.ncbi.nlm.nih.gov/books/NBK531716  |3 Volltext  |n NLM Bookshelf Books  |3 Volltext 
082 0 |a 610 
520 |a The four Botulinum neurotoxin type A (BoNT-A) products have different complex protein structures and differ in their molecular weights, pharmacologic profiles, and potency. Because each BoNT-A product has a different potency, they are not considered interchangeable by Health Canada and dosages may not covert directly on a 1 to 1 basis. Each BoNT-A has a different nonproprietary name (generic name) to make it more clear that the products are not interchangeable. However, switching may be necessary for patients who experience secondary nonresponse, develop side effects, or are required to do so for reasons related to drug coverage. For these reasons, it is important to be aware of the evidence to support the efficacy of switching between different BoNT-A products in experienced users. This report will review the evidence of clinical effectiveness of switching BoNT-A products for patients with upper limb spasticity (ULS) and cervical dystonia (CD) 

Similar Items